Literature DB >> 24519508

Inadvertent dexamethasone implant injection into the lens body management.

Antonio Berarducci1, Inderpaul S Sian, Roland Ling.   

Abstract

PURPOSE: Dexamethasone intravitreal implant is an approved preparation in the treatment of macular edema. The most common adverse reactions are increased intraocular pressure and cataract but the inadvertent injection of the dexamethasone implant into the capsular bag is an extremely rare event.
METHODS: We present a case of a 78-year-old man treated for persistence of cystoid macular edema (CME) with Ozurdex intravitreal implant in which the procedure was complicated by the injection of the dexamethasone implant into the lens body and discuss the management.
RESULTS: The patient underwent phacoemulsification of the lens, replacement of the Ozurdex, and implant of a 3-piece lens in the posterior chamber.
CONCLUSIONS: The injection of an intravitreal dexamethasone implant (Ozurdex) into the lens body is an extremely rare complication that can be effectively and successfully managed with the surgical extraction of the implant from the lens body and implant of a 3-piece intraocular lens in the sulcus.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24519508     DOI: 10.5301/ejo.5000436

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  11 in total

1.  Incomplete scleral penetration of dexamethasone (Ozurdex) intravitreal implant.

Authors:  Thomas Sherman; Vasant Raman
Journal:  BMJ Case Rep       Date:  2018-12-13

2.  Retinal injury following intravitreal injection of a dexamethasone implant in a vitrectomized eye.

Authors:  Seung Min Lee; Jae Woo Jung; Sung Who Park; Ji Eun Lee; Ik Soo Byon
Journal:  Int J Ophthalmol       Date:  2017-06-18       Impact factor: 1.779

3.  Intralenticular Ozurdex® - One Year Later.

Authors:  Kathleen A Regan; Charles R Blake; Zachary L Lukowski; Siva S R Iyer
Journal:  Case Rep Ophthalmol       Date:  2017-12-21

4.  Retinal injury following intravitreal injection of a dexamethasone implant in a non-vitrectimised eye.

Authors:  M Arvind Jain; Amishi Khanna; V Narendran
Journal:  Indian J Ophthalmol       Date:  2020-06       Impact factor: 1.848

5.  Intracrystalline Ozurdex®: therapeutic effect maintained for 18 months.

Authors:  Rodrigo Clemente-Tomás; Delia Hernández-Pérez; Paulina Neira-Ibáñez; Francisco Farías-Rozas; Raúl Torrecillas-Picazo; Vanesa Osorio-Alayo; Antonio M Duch-Samper
Journal:  Int Ophthalmol       Date:  2017-11-30       Impact factor: 2.031

6.  Immortal Ozurdex: A 10-month follow-up of an intralenticular implant.

Authors:  B Poornachandra; Vinod B M Kumar; Chaitra Jayadev; Subashchandra H Dorelli; Naresh Kumar Yadav; Rohit Shetty
Journal:  Indian J Ophthalmol       Date:  2017-03       Impact factor: 1.848

Review 7.  Dexamethasone intravitreal implant in the treatment of diabetic macular edema.

Authors:  Pravin U Dugel; Francesco Bandello; Anat Loewenstein
Journal:  Clin Ophthalmol       Date:  2015-07-16

8.  Intralenticular Sustained-Release Dexamethasone Implant: Is It Still Effective on Macular Edema?

Authors:  Mehmet Ali Sekeroglu; Mustafa Alpaslan Anayol; Fatih Koc; Hakan Tirhis; Seyhan Sonar Ozkan; Pelin Yilmazbas
Journal:  Case Rep Ophthalmol       Date:  2016-02-12

9.  Inadvertent intralenticular dexamethasone implant: 1-year follow-up and management.

Authors:  Cagatay Caglar
Journal:  Oman J Ophthalmol       Date:  2017 Sep-Dec

10.  Iatrogenic crystalline lens injury during intravitreal injection of triamcinolone acetonide: A report of two cases.

Authors:  Jing Su; Li-Jun Zheng; Xin-Quan Liu
Journal:  World J Clin Cases       Date:  2019-11-26       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.